An interventional study of Text messages in Type 2 Diabetes Mellitus and Physical Activity, sponsored by Samsung Medical Center. Status unknown at 1 site in Korea, Republic of. Open to participants aged 20 Years to 69 Years. Per ClinicalTrials.gov, last updated 2019-03-25.
Sponsored by Samsung Medical Center · Not applicable, Interventional, and Treatment
Among 569 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of — 68 open to participants now, 82 under way, 24 of them phase 3. Diabetes Mellitus, Type 2 · Korea, Republic of.
Among the 569 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of, this one is the 223rd largest by enrollment of the 491 interventional ones that give a count, is one of 27 that started in 2018, is one of 48 with no phase, and was the 320th registered.
10,371 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,406 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →68 of the 569 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Korea, Republic of, United States, Brazil and 7 more countries
AstraZeneca · Sites in Korea, Republic of, United States, Argentina and 13 more countries
AstraZeneca · Sites in Korea, Republic of, United States, Australia and 10 more countries
Eli Lilly and Company · Sites in Korea, Republic of, United States, Belgium and 8 more countries
AstraZeneca · Sites in Korea, Republic of, United States, Argentina and 10 more countries
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 373 (42%) set no upper age limit and 384 (43%) stop at 75 or younger; 52 take children under 18; 203 take healthy volunteers.
This study: 20 Years to 69 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
569 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 95 · Phase 2 34 · Phase 3 204 · Phase 4 116
First in 2001; this study’s year is marked. 27 started in 2018.
This study's enrollment of 200 is above the median of 80 across 8,350 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 173 across the 491 interventional studies, 1,470 across the 78 observational. Of the 432 that completed or were terminated, 159 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
433 of 569 have an industry lead sponsor. The 10 most frequent:
Samsung Medical Center is the lead sponsor of 1,011 studies on the registry; 152 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
Samsung Medical Center has 9 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
22 of the studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06220773Phase 3Boryung Pharmaceutical Co., LtdA Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy | 2026-12 |
| NCT07093476Phase 3CelltrionEfficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin | 2026-12 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07619833Phase 3Daewoong Pharmaceutical Co. LTD.To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes Mellitus | 2027-11 |
Among the 569 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this study, investigators measured the number of steps, blood pressure, blood glucose, and weight in daily life through the smartphone personal health record application for patients with type 2 diabetes. The efficacy of text message intervention, which encourages an increase in the number of steps per week for 12 weeks, on an increase in the number of daily steps and changes in glucose levels, weight, and blood pressure will be investigated. Also, the durability of intervention will be checked after 12 weeks of intervention ending.
This clinical study is a single institution, randomized, prospective study and monitors the average daily number of steps per week using a smartphone personal health record application developed by Samsung Medical Center for patients with type 2 diabetes. The study subjects were divided into five groups such as 1) basal activity (\<2500 steps/day), 2) limited activity (2500-4999 steps/day), 3) low activity (5000-7499 steps/day), 4) somewhat active (7500-9999 steps/day), 5) active (10000-12499 steps/day), 6) highly active (≥12500 steps/day)according to the average number of steps per day. During the 12-week period, the intervention group receives the text messages that encourage step-by-step increments every week, and the control group does not receive text messages. The effect of 12-week step monitoring and education on the change in daily step count will be analyzed. Also, the effect of change in daily step count on glucose level, body weight, and blood pressure will be studied.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intervention group receives weekly text messages which encourage the increment of daily step count
Other: Text messages
Control group does not receive text message
Text messages which encourage the increment of daily step count
change in daily step count after 12 weeks of intervention
change in daily step count after 12 weeks of intervention
Time frame: Week 12
mean daily step count after 12 weeks of intervention
mean daily step count after 12 weeks of intervention
Time frame: Week 12
the proportion of patients who reach participant-day during the 12 weeks of intervention
the proportion of patients who reach participant-day during the 12 weeks of intervention The participant-day means the day the participant reach thier upper group of daily step count
Time frame: Week 12
mean daily step count at Week 24
mean daily step count at Week 24
Time frame: Week 24
the proportion of patients who reach participant-day during the Week 13-24
the proportion of patients who reach participant-day during the Week 13-24
Time frame: Week 24
the proportion of patients whose HbA1c levels <6.5% without severe hypoglycemia
the proportion of patients whose HbA1c levels \<6.5% without severe hypoglycemia
Time frame: Week 12
the proportion of patients whose HbA1c levels <6.5% without severe hypoglycemia
the proportion of patients whose HbA1c levels \<6.5% without severe hypoglycemia
Time frame: Week 24
HbA1c levels
HbA1c levels (%)
Time frame: Week 12
HbA1c levels
HbA1c levels (%)
Time frame: Week 24
Fasting glucose levels
Fasting glucose levels (mg/dL)
Time frame: Week 12
Fasting glucose levels
Fasting glucose levels (mg/dL)
Time frame: Week 24
Body weight
Body weight (kg)
Time frame: Week 12
Body weight
Body weight (kg)
Time frame: Week 24
Blood pressure
Blood pressure (mmHg)
Time frame: Week 12
Blood pressure
Blood pressure (mmHg)
Time frame: Week 24
IPAQ (international physical activity questionnaire) score
IPAQ (international physical activity questionnaire) score are consisted of 7 questions regarding frequency of exercise, intensity of exercise, and duration of exercise. Using its automatic report, the results can be calculated as weekly physical activity level (low, intermediate, high).
Time frame: Week 12
IPAQ (international physical activity questionnaire) score
IPAQ (international physical activity questionnaire) score are consisted of 7 questions regarding frequency of exercise, intensity of exercise, and duration of exercise. Using its automatic report, the results can be calculated as weekly physical activity level (low, intermediate, high).
Time frame: Week 24
number of recordings on personal health record application
number of recordings on personal health record application
Time frame: Week 12
number of recordings on personal health record application
number of recordings on personal health record application
Time frame: Week 24
Total cholesterol
Total cholesterol (mg/dL)
Time frame: Week 12
Total cholesterol
Total cholesterol (mg/dL)
Time frame: Week 24
High-density lipoprotein cholesterol
High-density lipoprotein cholesterol (mg/dL)
Time frame: Week 12
High-density lipoprotein cholesterol
High-density lipoprotein cholesterol (mg/dL)
Time frame: Week 24
Triglycerides
Triglycerides (mg/dL)
Time frame: Week 12
Triglycerides
Triglycerides (mg/dL)
Time frame: Week 24
low-density lipoprotein cholesterol
low-density lipoprotein cholesterol (mg/dL)
Time frame: Week 12
low-density lipoprotein cholesterol
low-density lipoprotein cholesterol (mg/dL)
Time frame: Week 24
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2018 (actual). Primary completion is estimated for Sep 2019, 17 months after the start.
Of 2,066 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 17 months is below that.
Counting every sponsor, half of 2,243 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.